Prostate Cancer Institute

NUI Galway with the support of the Galway University Foundation has established a Prostate Cancer Institute directed by Professor Frank Sullivan.

{project_images} {/project_images}

The Institute, which is primarily focused on developing better therapies for patients with prostate cancer, will benefit from a close association with the extensive clinical services already offered to these patients at University Hospital Galway (UHG) and other regional hospitals. The Institute will also collaborate with the wide-ranging biomedical research programmes of the National Centre for Biomedical Engineering Sciences (NCBES) at NUI Galway and with a number of research institutes in Ireland and internationally.

Cancer Biology and Developmental Therapeutics are strategic research priorities at NUI Galway. Over the last number of years, NUI Galway and UHG have built a strong team of internationally recognised pre-clinical, translational and clinical cancer scientists. University Hospital Galway is the major academic medical centre in the West of Ireland and is one of the eight specialist cancer centres established under the National Cancer Control Plan. As such, it offers the full range of prostate cancer diagnostics and treatments and is one of the country’s leading centres for treatment of this form of cancer. 

Prostate cancer still claims around 550 lives a year in Ireland, rivalling the number of deaths due to breast cancer.

The Prostate Cancer Institute will draw on the expertise of clinicians and scientists from the University and Hospital in its commitment to develop effective new therapies for patients with prostate cancer. While many advances have been made in the management of early stage patients, a subset of these men will relapse and die of the disease. New and more effective therapies are urgently needed for patients with relapsed disease or disease which is relatively resistant to current standard therapies.

Initial funding for the Institute has been provided by Galway University Foundation. This has enabled the Institute to appoint Dr. Sharon Glynn as Director of Laboratory Research. Early work at the Institute will involve the collection and bioprocurement of prostate tissue which will provide the base for its primary and collaborative research programme.

For further information on the Prostate Cancer Institute, please email Susan Moore or telephone 091 495497.